Skip to main content
. Author manuscript; available in PMC: 2023 Sep 1.
Published in final edited form as: J Am Pharm Assoc (2003). 2022 Apr 12:S1544-3191(22)00123-6. doi: 10.1016/j.japh.2022.04.005

Table 2.

Patient demographics and clinical characteristics

All Patients (N=100) Baseline MRCI score, mean (95% CI)
Age, mean ± SD, y 9.5 ± 0.6 32.6 (29.3–35.8)
Sex, n (%), male 58 (58) 32.6 (28.3–36.9)
Race, n (%)
 White 53 (53) 33.7 (29.3–38.0)
 Other 20 (20) 30.5 (23.4–37.5)
 Black or African American 12 (12) 35.5 (21.3–49.7)
 >1 Race 7 (7) 25.7 (22.2–29.2)
 Asian 6 (6) 36.4 (27.2–45.7)
 American Indian or Alaskan Native 1 (1) 26.5
 Unknown 1 (1) 12.5
Ethnicity, n (%)
 Hispanic or Latino 53 (53) 30.4 (26.8–33.9)
 Not Hispanic or Latino 46 (46) 35.5 (29.9–41.2)
 Unknown 1 (1) 12.5
Insurance type, n (%)
 Public 83 (83) 31.6 (28.0–35.2)
 Private 17 (17) 37.2 (30.0–44.4)
High-risk medications, n (%)
 0–1 39 (39) 27.4 (23.6–31.3)
 2–3 30 (30) 28.6 (24.4–32.8)
 ≥4 31 (31) 42.9 (35.6–50.2)
Any compounded medications, n (%)
 Yes 14 (14) 32.7 (23.2–42.2)
 No 86 (86) 32.6 (29.1–36.0)
Complex chronic conditions, n (%)
 0 11 (11) 26.5 (15.6–37.4)
 1–2 47 (47) 29.6 (25.1–34.0)
 ≥3 42 (42) 37.6 (32.8–42.3)
Outpatient visits in past year, n (%)
 0–9 55 (55) 27.5 (23.9–31.2)
 10–19 27 (27) 33.2 (27.3–39.1)
 20–29 11 (11) 51.3 (41.1–61.5)
 ≥30 7 (7) 40.6 (27.2–53.9)